PCYC

Pharmacyclics, Inc. (PCYC)

$91.86
*  
2.87
 negative 
3.23%
Get PCYC Alerts
*Delayed - data as of Apr. 15, 2014 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time

Pharmacyclics, Inc. (PCYC)

Q2 2013 Earnings Call

February 14, 2013, 4:30 p.m. ET

Executives

Francis Irvine

Josh Brumm - EVP, Finance

Bob Duggan - Chairman and CEO

Urte Gayko, Ph.D. – Vice President, Global Regulatory Affairs

Dr. Lori Kunkel - Chief Medical Officer

Dr. Maky Zanganeh – COO

Paula Boultbee - EVP, Sales and Marketing

Dr. Maria Fardis – EVP, Operations and Alliances

Dr. Jesse McGreivy - VP, Clinical Science

Dr. Joe Buggy - VP, Research

Rich Love - VP, Legal

Rainer (Ramses) Erdtmann - Vice President, Finance & Administration

Jesse McGreivy - Vice President, Clinical Science

Analysts

Michael J. Yee – RBC Capital Markets

Geoffrey Porges (Yon) - Sanford Bernstein

Joel Sendek - Stifel Nicolaus

Jason Cantor – Credit Suisse

Mike King – JMP Securities

Alan Carr (Mark) – Needham & Company

Jason Cantor – Credit Suisse

Greg Wade – Wedbush Securities

(Jay Sotherman – Kohls Capital)

Presentation

Operator

Operator

Greetings and welcome to the Pharmacyclics' quarterly conference call. (Operator Instructions)

It is now my pleasure to introduce your host, Ramses Erdtmann. Thank you Mr. Erdtmann, you may now begin.

Ramses Erdtmann

Thank you, Sharon and good afternoon and thank you for joining us for our conference call today.

With me on the call and available to answer questions are our CEO and Chairman of the Board, Bob Duggan, our Chief Operating Officer, D&R. Maky Zanganeh, our Chief Medical Officer, D&R. Lori Kunkel, our Executive Vice President, Sales and Marketing, Paula Boultbee, our Executive Vice President of Finance, Josh Brumm, our Executive Vice President of Operations an Alliances, Dr. Maia Fardis, our Vice President of Clinical Science, D&R. Jesse McGreivy, our Vice President of Global Regulatory Affairs, Dr. Urte Gayko, our Vice President of Research, Dr. Joe Buggy, and our Vice President of Legal, Rick Love.

Our genre for today's call will include a review of our financials, brief comments on the quarter by our CEO, an update of our most recent regulatory success, and a summary of our clinical progress as well as an outlook of what to expect in 2013.

Before we start, let me remind you that this non-confidential presentation contains forward-looking statements about the business, prospects of Pharmacyclics including expectations regarding Pharmacyclics' financial performance, commercial products, and potential future products in different areas of therapeutic research and development.

Results may differ materially depending on the progress of Pharmacyclics' product program, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market, and developments by competitors, and those factors detailed in Pharmacyclics' filings with the SEC such as the 10-Q, 10-K, and 8-K reports.

I would now like to turn this call over to Josh Brumm, our Executive Vice President of Finance. Josh.

Josh Brumm

Thank you, Ramses, and good afternoon to everybody on the call.

I would like to begin by mentioning that Pharmacyclics announced on November 14th, 2012, that the company has changed its fiscal year end from June 30 to September 31.

Effective September 31, 2012, as a result of the six months ended December 31st, 2012, represents a transition period. And the company's net fiscal year will cover the period from January 1, 2013 to December 31, 2013.

On this call, I will provide operating results for the six and three months ended December 31, 2012.

The company's GAAP net income for the six months ended December 31, 2012, was $117.5 million or $1.69 basic and $1.58 diluted earnings per share. Compared to the six months ended December 31, 2011, GAAP net income of $41.7 million or $0.61 basic and $0.58 diluted earnings per share.

With respect to non-GAAP adjusted for stock based compensation for the six months ended December 31, 2012, net income was $125 million or $1.79 basic and $1.68 diluted earnings per share compared to non-GAAP net income of $46.3 million or $0.68 basic and $0.65 diluted earnings per share for the same period of the prior year.

The increase in net income from the year-over-year primarily relates to higher collaboration revenue earned as we achieved three milestones of $50 million each aggregating to $150 million for the six months ended December 31st, 2012 as compared to $70.6 million in licensed revenue recognized from the upfront payment received from Janssen during the six months ended December 31st, 2011.

In regards to the company's three month period ended December 31st, 2012, GAAP net income was $41.9 million or $0.60 basic and $0.56 diluted earnings per share compared to GAAP net income of $56.3 million or $0.82 basic and $0.78 diluted earnings per share for the quarter ended December 31st, 2011.

On a non-GAAP basis, net income reported for the quarter ended December 31st, 2012, was $46.2 million or $0.66 basic and $0.62 diluted earnings per share compared to non-GAAP net income of $58.6 million or $0.85 basic and $0.82 diluted earnings per share for the same period of the prior year.

The decrease in net income for the quarter ended December 31st, 2012 as compared to the quarter ended December 31st, 2011 primarily relates to lower license and milestone revenue earned during the quarter and higher general and administrative expenses.

Revenue for the six months ended December 31st, 2012 was a $160.7 million compared to $77.9 million for the six months ended December 31st, 2011.

Revenue for the quarter ended December 31, 2012 was $58 million compared to $77.9 million for the quarter ended December 31st, 2011. And revenues for the quarter ended December 31, 2012 includes $50 million of milestones revenue due to the company's achievement of one clinical milestone in connection with the collaboration agreement with Janssen as well as a $5 million license revenue related to our license agreement with Novo.

Read the rest of this transcript for free on seekingalpha.com